// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Fourth-line targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

Igor Stukalin - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

A phase II trial of zoptarelin doxorubicin in castration- and taxane-resistant prostate cancer.

Steven Yu - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Zoptarelin doxorubicin

Pre-treatment PSA- progression as a negative prognostic factor in patients using 5-alpha-reductase inhibitors prior to radiotherapy for prostate cancer.

Daniel Taussky - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Early docetaxel-resistance in metastatic hormone-sensitive prostate cancer.

Nedal Bukhari - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Predicting disease progression in men with localized high risk prostate cancer undergoing radical prostatectomy.

Yaw A. Nyame - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Circulating tumor (ct)-DNA alterations in metastatic castration-resistant prostate cancer (mCRPC): Association with outcomes and evolution with therapy.

Guru Sonpavde - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Long-term incidence of venous thromboembolic events following cystectomy: A population-based analysis.

Christopher J.D. Wallis - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Psychosocial Distress in Chronic Kidney Disease: Benefits of Kidney Transplantation.

C. Richardson - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: Effect of atezolizumab on 12-month survival.

Gregory Russell Pond - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Atezolizumab

Racial Differences in Liver Cirrhosis-Related Mortality Among Patients with Model for End-Stage Liver Disease Sodium Score (MELDNa) ≤ 15.

K. Atiemo - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Gastroenterology (GU)

N/A

N/A

Raising Awareness of the Importance of Exercise Training in Solid Organ Transplant: A Description of a Canadian Knowledge Dissemination Project.

T. Janaudis-Ferreira - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

RAS Inhibition Attenuates Urine Angiotensin II-Regulated Proteins Associated with Interstitial Fibrosis and Tubular Atrophy in Kidney Transplant Recipients.

Z. Mohammed-Ali - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Angiotensin II

Recurrent HCC After Radiofrequency Ablation or Liver Resection Can Be Effectively Treated with Salvage Transplantation.

H. Muaddi - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Refinement of an Old Faithful: A Standardized Flow Cytometry Approach to Measure Donor-Recipient Alloreactivity (a Pilot Study).

A. Halpin - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation.

N. Lam - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Renal Function, Albuminuria, and the Risk of Death and Graft Loss After Kidney Transplantation.

N. Lam - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

N/A

Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens.

Paul L. Nguyen - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Androgen Tear

Genomic architecture of radioresistant prostate cancer.

Melvin Chua - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

N/A

Retrospective Review of Early versus Late Initiation of Oral Sildenafil for Right Ventricular Dysfunction in Post-Cardiac Transplant Surgery Patients.

P. Brown - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

Sildenafil citrate

Review of UK-Wide Practice of Pancreas Transplantation: Donor Selection, Back-Bench Preparation & Implantation Technique.

H. Sharma - American Transplant Congress (ATC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved